Sugi Predict

Sugi Predict / Compounds / SCHEMBL3335304

SCHEMBL3335304

SCHEMBL3335304

NC(=O)OCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.58
▸ MAOB P27338 6/20 0.58
▸ KMT2A Q03164 2/20 0.54
▸ MMP12 P39900 2/20 0.52
▸ MMP1 P03956 1/20 0.52
▸ KIF11 P52732 1/20 0.50
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.46
▸ PPARG P37231 2/20 0.45
▸ PPARA Q07869 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720920 0.86 MAOB (0.55) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL25290310 0.85 IDO1 (0.57) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL30437401 0.84 KMT2A (0.50) IDO1KMT2AMEN1CYP1A2ALDH1A1
SCHEMBL11841969 0.83 IDO1 (0.55) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL2364381 0.82 TAAR1 (0.52) IDO1MAOBKMT2AKIF11TAAR1
SCHEMBL6921092 0.82 IDO1 (0.55) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL6026962 0.81 IDO1 (0.53) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL13542853 0.81 ALDH1A1 (0.58) IDO1MAOBKMT2AMMP12MMP1
SCHEMBL8198450 0.81 ALDH1A1 (0.58) IDO1MAOBKMT2AMMP12MMP1
Hydrochloric Acid SCHEMBL11841966 0.81 IDO1 (0.56) IDO1MAOBKMT2AMMP12MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144801-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-06-10 — — US claimed
EP-2076261-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2009-07-08 — — EP claimed
WO-2008041184-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-04-10 — — WO claimed
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2025-12-18 — — US disclosed
US-20250340514-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2025-11-06 — — US disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 — — EP disclosed
US-12398103-B2 3-diarylmethylenes and uses thereof ATUX ISKAY LLC (US) 2025-08-26 — — US disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 — — US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 — — US disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 — — WO disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 — — EP disclosed
WO-2018050795-A1 PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS BASF SE (DE) 2018-03-22 — — WO disclosed
WO-2018050793-A1 PROCESS FOR PREPARING PHOSPHONIUM SALT ESTERS AS BUILDING BLOCKS FOR CAROTENOIDES BASF SE (DE) 2018-03-22 — — WO disclosed
WO-2018050794-A1 PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS BASF SE (DE) 2018-03-22 — — WO disclosed
CN-107406464-A Arginase inhibitor and its therapeutical uses 昂科艾伦迪治疗法股份公司 2017-11-28 — — CN disclosed
WO-2016199761-A1 DIFLUOROMETHYLENE COMPOUNDS 石原産業株式会社 2016-12-15 — — WO disclosed
CN-102300847-A PPAR agonist compositions and methods of use thereof — 2011-12-28 — — CN disclosed
EP-2076261-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2009-07-08 — — EP disclosed
WO-2008041184-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-04-10 — — WO disclosed
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 IDO1 3900/4885MAOB 3722/4885KMT2A 742/4885
US-12398103-B2 3-diarylmethylenes and uses thereof MYC, MYCBP, FOXO1 IDO1 3900/4885MAOB 3722/4885KMT2A 742/4885
US-20100144801-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM5 IDO1 583/4885MAOB 471/4885KMT2A 2144/4885
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 IDO1 2586/4885MAOB 2708/4885KMT2A 4002/4885
US-20250340514-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 IDO1 3900/4885MAOB 3722/4885KMT2A 742/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB IDO1 1908/4885MAOB 2156/4885KMT2A 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.